Baricitinib 2 MG Oral Tablet

DRUG2 trials

Sponsors

William Tyor, University Hospital, Brest

Conditions

Human Immunodeficiency VirusPolymyalgia Rheumatica (PMR)

Phase 2

Baricitinib for Reduction of HIV - CNS

RecruitingNCT05452564

William TyorHuman Immunodeficiency Virus

Start: 2023-05-18End: 2028-01-01Target: 95Updated: 2026-03-23

Phase 3

Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica

Not yet recruitingNCT07279688

University Hospital, BrestPolymyalgia Rheumatica (PMR)

Start: 2025-12-12End: 2029-06-12Target: 140Updated: 2025-12-12

Related Papers

Sustained antiviral response against in vitro HIV-1 infection in peripheral blood mononuclear cells from people with chronic myeloid leukemia treated with ponatinib

Frontiers in Pharmacology2024-09-232 citations